NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Amicus Therapeutics, Inc. (“Amicus Therapeutics” or the “Company”) (NASDAQ: FOLD) concerning possible violations of federal securities laws by certain officers and directors.
On November 28, 2016, Amicus Therapeutics shares fell after hours following an announcement that the Food and Drug Administration will not grant an accelerated approval for its drug migalastat to treat Fabry disease. Shares of Amicus Therapeutics were down more than 21% on intraday trading on November 29, 2016. To obtain additional information about the investigation, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.